Spark Therapeutics (ONCE) Misses Q2 EPS by 35c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Spark Therapeutics Reports Second Quarter 2015 Results
August 5, 2015 8:01 AM EDTPHILADELPHIA, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE) today announced financial results for the quarter ended June 30, 2015 and highlighted its product development progress.
"During the past quarter we've made great strides in advancing our clinical programs and we are reaffirming our guidance to report top-line results from our pivotal Phase 3 trial of SPK-RPE65 before the end of the year," said Jeffrey D. Marrazzo, co-founder and chief executive officer of Spark. "We also expanded our preclinical pipeline with both the selection of a lead program in the area of neurodegenerative... More
